FDA expands approved age indication for GSK RSV vaccine in higher risk adults.
The US Food and Drug Administration has expanded the approved age indication of GSK's respiratory syncytial virus vaccine, Arexvy, to adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV.
Source: Sharecast
GSK noted on Friday that the vaccine was previously approved in the US for the prevention of RSV-related LRTD in adults aged 60 and older, and adults aged 50-59 at increased risk for LRTD caused by RSV. It is not for use in pregnant women.
Sanjay Gurunathan, GSK head of vaccines and infectious diseases research and development, said: "This age expansion can help address a significant medical need for adults in the United States at higher risk of severe RSV disease due to certain underlying conditions, and help ease pressure on the healthcare system.
"We are proud of this latest step in our strategy to bring RSV prevention to broader adult populations."
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
